Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maintenance-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia-lymphoblastic lymphoma
- Development stage
- Phase 3
- Lead developer
- GIMEMA
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
This refers to the maintenance chemotherapy phase of the GIMEMA LAL1913 clinical trial protocol, a Phase 2 pediatric-inspired treatment regimen developed by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA). The protocol is designed for adult patients (aged 18-65) with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). While the overall protocol features pegaspargase (a pegylated form of the enzyme L-asparaginase) during induction and consolidation to achieve early minimal residual disease (MRD) negativity, the maintenance phase is specifically administered to patients who achieve a complete response and are classified as standard risk or MRD-negative. The regimen aims to improve long-term outcomes, with the trial reporting a 3-year overall survival rate of 66.7% and disease-free survival of 63.3%.
- Other names
- GIMEMA LAL1913 Maintenance PhaseMaintenance therapy (GIMEMA LAL1913)
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on maintenance-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia-lymphoblastic lymphoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maintenance-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia-lymphoblastic lymphoma.